Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

Emerald Logic FACET software generates predictive models and identifies novel variables driving RVX-208 drug efficacy, safety and reduced MACE incidence

TSX Exchange Symbol: RVX

CALGARY, March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics.  Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE. The objective of this collaborative program was to develop quantitative models and identify variables that contribute to drug response, and the incidence of major adverse cardiac events (MACE). 

"We are delighted to work with the Resverlogix team in this exciting area of epigenetic drug development and BET inhibition," stated Mr. Patrick Lilley, president and chief executive officer of Emerald Logic Inc. "Resverlogix's clinical dataset, consisting of patients treated with the first BET inhibitor to be tested in the clinic, provides an unprecedented opportunity to examine factors contributing to drug efficacy, major adverse cardiac events and safety for this drug class."

The complete dataset, containing approximately 650,000 data points, was analyzed using Emerald Logic's FACET software. This unique approach combines medical history, epidemiology, demographics, patient vital signs, and clinical lab measures in order to identify explanatory factors for efficacy and adverse events and to produce discriminatory models without bias or guidance. "Our clinical dataset is a powerful repository that can be mined to understand variables that drive vascular risk and drug response," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "Emerald Logic has completed many healthcare projects and the computational power of its software has produced accurate and insightful results that are outside the capabilities of currently practiced methods," Mr. McCaffrey added.

The collaboration generated multiple proprietary models and deduced both binary and continuous variables, previously unidentified, that contribute to drug efficacy, adverse events and most importantly to the observed reduction in MACE incidence in response to treatment with RVX-208. The Company plans to file new intellectual property surrounding these variables and algorithms and intends to integrate and assess them in upcoming clinical trials for the purpose of patient enrichment and safety monitoring. "With the addition of every new clinical data point from upcoming trials, the models will continue to evolve and strengthen their predictive ability for future patient screening and targeting," stated Mr. McCaffrey. "The variables identified have already provided Resverlogix with novel avenues for exploration in patients with cardiovascular disease and diabetes mellitus, and in the mitigation of adverse events."

About RVX-208

RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET-Bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes either on or off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with disease such as cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with diabetes mellitus and low HDL.

About Resverlogix

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on Twitter @Resverlogix_RVX and our blog at

About Emerald Logic

Emerald Logic is a privately held, leading informatics company that solves hyper-dimensional analytical problems for personalized medicine, predictive healthcare and biomarker discovery.  The company's proprietary Fast Collective Evolution Technology (FACET) system is currently being used by top pharmaceutical and biotech research companies and combines biological and mathematical principles to address high-impact questions that currently elude conventional statistics, business intelligence and traditional artificial intelligence (AI) methods.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252

Patrick Lilley
President and CEO
Emerald Logic, Inc.
Phone: 714-225-1561


Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: 212 845 4251
Phone: 212-845-4272

SOURCE Resverlogix Corp.


Organization Profile

Resverlogix Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890